Retatrutide fatigue is one of the most commonly reported side effects in clinical trials of this investigational triple receptor agonist, yet many people are uncertain how long it lasts and what to expect. Retatrutide (LY3437943) simultaneously activates GLP-1, GIP, and glucagon receptors, making it pharmacologically distinct from semaglutide or tirzepatide. Understanding why tiredness occurs, how it typically progresses during dose escalation, and when to seek medical advice can help patients and clinicians manage this side effect more effectively. This article draws on available Phase 2 trial data and related incretin therapy experience to provide clear, evidence-informed guidance.

Why Retatrutide Can Cause Fatigue

Retatrutide causes fatigue primarily through appetite suppression reducing caloric intake, gastrointestinal side effects causing dehydration, and metabolic adaptation — with possible central nervous system effects via GLP-1 receptor activation in the brain.

Retatrutide (also referred to as LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor mechanism distinguishes it from earlier agents such as semaglutide and tirzepatide. It is important to note that retatrutide has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and remains under clinical investigation. It should only be used within the context of a clinical trial or an appropriate supervised access pathway — unsupervised procurement or use is not recommended.

Fatigue has been reported by participants in clinical trials of retatrutide, though precise frequency data from published safety tables remain limited at this stage of development. Several mechanisms are thought to contribute, and these should be understood as hypotheses based on the drug's pharmacology and observations from related incretin-based therapies:

• Reduced caloric intake: Retatrutide significantly suppresses appetite, often leading to a substantial reduction in food consumption. Lower energy intake may directly result in feelings of tiredness and low energy, particularly in the early weeks of treatment.

• Gastrointestinal side effects: Nausea, vomiting, and diarrhoea — which are frequently reported in trial data — can lead to dehydration and electrolyte imbalances, both of which may contribute to fatigue.

• Metabolic adaptation: As the body adjusts to altered glucose metabolism and changes in energy utilisation, temporary fatigue may arise during this transitional period. The extent to which glucagon receptor activation influences energy expenditure in humans remains an area of ongoing research.

• Central nervous system effects: GLP-1 receptors are present in the brain, and their activation is hypothesised to influence neurological pathways associated with energy levels and alertness, though this mechanism has not been fully established in humans.

Fatigue in this context is generally considered a physiological response to the drug's mechanism rather than a sign of serious harm, though it should always be monitored carefully. Any suspected side effects should be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

How Long Fatigue Typically Lasts During Treatment

Fatigue is most pronounced during dose escalation and commonly begins to improve once the dose stabilises, though retatrutide-specific week-by-week timeline data remain limited from published Phase 2 trial results.

Data from the 2023 Phase 2 retatrutide trial published in the New England Journal of Medicine (NEJM) provide the primary available evidence on the safety and tolerability of retatrutide, including adverse effects such as fatigue. However, the published data do not provide detailed week-by-week fatigue timelines, and retatrutide-specific evidence on the precise duration of tiredness remains limited.

Based on the available trial data and patterns observed with related incretin-based therapies, fatigue associated with retatrutide is thought to be most pronounced during the dose escalation phase. As the body adapts to the medication and caloric intake stabilises, fatigue may begin to improve for many individuals. However, it is important to note that these patterns are extrapolated in part from experience with other GLP-1-based agents, and individual responses to retatrutide may differ.

A broad, indicative timeline — to be interpreted with caution — may look as follows:

• Early weeks of treatment: Fatigue may be most noticeable, coinciding with appetite suppression and initial gastrointestinal adjustment.

• During dose escalation: Fatigue may persist or temporarily worsen with each dose increase, in line with observations from the Phase 2 trial protocol.

• Once the dose stabilises: Fatigue commonly begins to improve for many participants, though some may continue to experience mild tiredness, particularly if gastrointestinal side effects persist.

Because retatrutide is not yet licensed for clinical use in the UK, these timelines are drawn from trial data rather than real-world clinical experience. Healthcare professionals and patients should be aware that individual responses may differ significantly from trial averages, and that fatigue persisting beyond a few weeks or worsening at any stage warrants clinical review.

Factors That Affect the Duration of Tiredness

Dose escalation speed, nutritional adequacy, hydration status, pre-existing conditions such as anaemia or hypothyroidism, and sleep quality all influence how long retatrutide-related fatigue persists.

The duration and severity of fatigue whilst taking retatrutide are not uniform across individuals. A range of physiological, lifestyle, and treatment-related factors can influence how long tiredness persists.

Dose and escalation schedule play a significant role. Higher doses are associated with greater appetite suppression and more pronounced gastrointestinal effects, both of which can prolong fatigue. A slower, more gradual dose escalation — as is standard practice with GLP-1-based therapies — may help mitigate the intensity and duration of tiredness.

Nutritional adequacy is another critical factor. Individuals who significantly restrict their caloric intake, whether intentionally or as a result of nausea, are at greater risk of prolonged fatigue due to insufficient macronutrient and micronutrient intake. In particular, inadequate protein, iron, B vitamins, and complex carbohydrates can all exacerbate tiredness. If a nutritional deficiency is suspected, it is important to discuss this with a GP or dietitian and arrange appropriate testing before starting any supplementation, rather than supplementing without assessment.

Other relevant factors include:

• Pre-existing conditions: Anaemia, hypothyroidism, sleep apnoea, and depression can all independently cause fatigue and may compound drug-related tiredness, making it harder to distinguish the cause.

• Hydration status: Gastrointestinal side effects such as vomiting and diarrhoea increase the risk of dehydration, which is a well-recognised contributor to fatigue. Maintaining adequate fluid intake is important, though individuals with conditions requiring fluid restriction — such as heart failure or chronic kidney disease — should follow the specific guidance given by their clinical team.

• Sleep quality: Weight loss and metabolic changes can sometimes temporarily disrupt sleep patterns, indirectly worsening daytime tiredness.

• Physical activity levels: Whilst exercise may feel challenging when fatigued, maintaining gentle activity can support energy regulation and metabolic adaptation.

Understanding these contributing factors allows both patients and clinicians to take a more targeted approach to managing fatigue, rather than attributing all tiredness solely to the medication itself.

Managing Fatigue Safely Whilst Taking Retatrutide

Maintaining adequate protein, complex carbohydrates, and fluid intake, pacing activity, and avoiding alcohol are key evidence-informed strategies for managing retatrutide fatigue safely.

Whilst fatigue during retatrutide treatment is often self-limiting, there are several evidence-informed strategies that may help reduce its impact on daily life. These approaches are broadly consistent with guidance used for managing fatigue associated with other GLP-1 receptor agonists, as reflected in NHS and NICE resources for weight management pharmacotherapy (including NICE TA875 on semaglutide for weight management).

Nutritional support is a priority. Even when appetite is significantly reduced, it is important to maintain adequate intake of:

• Protein (to preserve lean muscle mass and support energy)

• Complex carbohydrates (to sustain blood glucose levels)

• Iron, B12, and folate (to help prevent nutritional anaemia — if deficiency is suspected, speak to a GP for testing before starting supplements)

• Fluids — aim for around 6–8 drinks per day (approximately 1.2–1.5 litres), in line with NHS hydration guidance. Those with conditions requiring fluid restriction, such as heart failure or chronic kidney disease, should follow their clinician's specific advice rather than general targets.

Eating smaller, more frequent meals rather than large portions may help manage nausea whilst ensuring sufficient caloric intake.

Pacing and rest are also important. During the initial weeks of treatment, it is reasonable to reduce the intensity of physical activity and prioritise adequate sleep. As fatigue improves, gradually reintroducing moderate exercise — such as walking or swimming — can help restore energy levels and support metabolic health.

Safety during daily activities: If fatigue or dizziness is significant, avoid driving or operating heavy machinery until symptoms have resolved. This is particularly important following dose increases.

Avoiding compounding factors is equally valuable. Limiting alcohol, which can worsen fatigue and interact with metabolic processes, and maintaining a consistent sleep schedule are both practical steps. If caffeine is used to manage tiredness, it should be consumed in moderation and not as a substitute for addressing the underlying cause.

Finally, keeping a simple symptom diary can help identify patterns — for example, whether fatigue worsens after dose increases — and provides useful information to share with a healthcare professional at follow-up appointments.

When to Seek Medical Advice About Persistent Fatigue

Seek prompt medical advice if fatigue is severe, worsening, or accompanied by dizziness, pallor, low mood, or abdominal pain; call 999 or attend A&E if severe upper abdominal pain or chest pain develops.

Whilst fatigue during retatrutide treatment is commonly expected and usually resolves with time, there are specific circumstances in which it is important to seek prompt medical advice. Because retatrutide is not yet licensed in the UK, individuals accessing it through clinical trials or other supervised routes should have a clearly identified healthcare contact for safety concerns.

Seek advice sooner rather than later — do not wait until 12 weeks if fatigue is severe, worsening, or significantly affecting daily life. Contact your GP, study team, or supervising clinician if fatigue:

• Is severe enough to significantly impair daily functioning, work, or personal care

• Persists without any improvement despite the dose stabilising

• Is accompanied by dizziness, fainting, or palpitations, which may suggest dehydration or electrolyte disturbance

• Occurs alongside unexplained weight loss beyond expected levels, pallor, or breathlessness — which could indicate nutritional anaemia

• Is associated with low mood, persistent sadness, or loss of motivation, as these may suggest depression rather than drug-related tiredness

• Develops alongside jaundice, dark urine, or abdominal pain, which warrant urgent assessment to exclude hepatic or pancreatic causes

Seek urgent medical attention (call 999 or go to A&E) if you experience:

• Severe, persistent upper abdominal pain, particularly if it radiates to the back and is accompanied by vomiting — these are potential symptoms of pancreatitis and require immediate assessment

• Chest pain, severe dizziness, confusion, or an inability to keep any fluids down

For urgent advice that does not require emergency services, contact NHS 111 (online at 111.nhs.uk or by telephone).

It is also important to rule out unrelated medical causes of fatigue, particularly if the tiredness feels disproportionate to the degree of appetite suppression or gastrointestinal symptoms experienced. A GP can arrange basic investigations — including a full blood count, thyroid function tests, and iron studies — to exclude common treatable causes.

If you are participating in a clinical trial or receiving retatrutide under specialist supervision, any decision to pause or stop treatment should be discussed with your study team or supervising clinician. Do not make changes to your treatment without their guidance, as this may affect glycaemic control or weight management outcomes. There is no established link between retatrutide and serious long-term fatigue disorders, but all persistent or unexplained symptoms deserve thorough clinical evaluation.

Suspected side effects should be reported via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Frequently Asked Questions